ConcertAI Integrates ASCO Guidelines into Precision Suite and CancerLinQ SmartLinQ Solutions for Enhanced Biopharma Research

ConcertAI Integrates ASCO® Guidelines into Its Generative and Agentic AI Precision Suite™ and CancerLinQ® SmartLinQ™ Solutions CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI, a leading provider of oncology-focused artificial intelligence (AI) and multi-modal data (MMD) solutions for healthcare and life sciences, has announced the integration of American Society of Clinical Oncology (ASCO) Guidelines into its CARAai platform. This move enhances ConcertAI's Precision Suite and CancerLinQ® SmartLinQ™ solutions, allowing biopharma researchers and clinicians to better assess guideline-concordant care and treatment outcomes. The ASCO Guidelines are widely recognized as authoritative standards for cancer care, offering evidence-based recommendations for diagnosis, treatment, and patient management. By incorporating these guidelines into its AI platform, ConcertAI aims to improve the accuracy and relevance of its data-driven insights. The Precision Suite, known for its low-latency and high-recency data capabilities, now provides real-time analysis that aligns with the latest clinical recommendations. This integration ensures that researchers and healthcare providers have immediate access to up-to-date, guideline-concordant information, which can significantly impact the design and execution of clinical studies and patient care plans. CancerLinQ® SmartLinQ™, another key solution from ConcertAI, also benefits from this integration. SmartLinQ™ is designed to help clinicians make informed decisions at the point of care by providing comprehensive, personalized treatment options based on the latest research and best practices. With the inclusion of ASCO Guidelines, the platform can now offer even more tailored and evidence-based recommendations, enhancing patient outcomes and reducing variability in care. Dr. Andrew N. Rosenberg, Chief Medical Officer of ConcertAI, stated, "Integrating ASCO Guidelines into our solutions represents a major step forward in our mission to advance precision oncology. By leveraging the latest clinical insights, we can support both researchers and clinicians in making the most informed and effective decisions." The enhanced Precision Suite and SmartLinQ™ solutions are expected to have several benefits. For researchers, the integration means more robust and reliable data sets for clinical trials, leading to higher-quality studies and potentially faster drug development processes. For clinicians, it translates to better-informed treatment decisions, improved patient outcomes, and greater adherence to standardized care protocols. Furthermore, ConcertAI's multi-modal data approach, which combines diverse data sources including electronic health records, imaging results, and genomics data, allows for a holistic view of patient health. This comprehensive data set is crucial for generating nuanced, context-aware insights that can inform complex treatment decisions and patient-specific care plans. "By aligning with ASCO Guidelines, we are ensuring that our AI solutions are not only technologically advanced but also clinically relevant," said Dr. Rosenberg. "This is essential for building trust among our users and delivering meaningful improvements in oncology care." ConcertAI's commitment to innovation in oncology care is evident in this new integration. The company continues to push boundaries by combining cutting-edge AI with actionable clinical data, ultimately aiming to transform the way cancer is treated and researched. This step is a significant milestone in the ongoing effort to personalize and optimize cancer care, marking a new era of collaboration between technology and clinical expertise in the fight against cancer.